Director of Pulse Biosciences Purchases Nearly $1 Million in Shares

On December 13th, Robert W. Duggan, a director at Pulse Biosciences, Inc. (NASDAQ:PLSE), made a significant purchase of 55,256 shares of the company’s stock. The shares were acquired at an average price of $17.18 each, amounting to a total investment of $949,298.08. After this transaction, Duggan's total holdings in Pulse Biosciences increased to 42,328,717 shares, which are valued at approximately $727,207,358.06. This acquisition represents a small increase of 0.13% in his overall stake in the company. Details of the transaction were filed with the Securities and Exchange Commission (SEC) and can be accessed through their official filings.

Pulse Biosciences Stock Performance

During midday trading on Tuesday, Pulse Biosciences stock (PLSE) saw a slight uptick, rising by $0.07 to reach $19.24. A total of 157,588 shares were traded, which is lower than the average trading volume of 201,113. Over the past year, the stock has fluctuated significantly, achieving a low of $6.59 and a high of $22.69. The stock's fifty-day moving average price is currently $17.74, while the 200-day moving average stands at $16.50.

Recent Earnings Report

Pulse Biosciences recently released its quarterly earnings report on October 30th. For the quarter, the company reported a loss of $0.21 per share, which is a slight decline compared to the loss of $0.19 per share reported during the same period last year.

Institutional Activity

Several institutional investors have been actively buying and selling shares of Pulse Biosciences in recent months. Price T Rowe Associates Inc. MD purchased a new stake valued at approximately $88,000 in the first quarter. Similarly, Cetera Advisors LLC acquired a new position worth about $109,000 during the same period. In addition, Bank of New York Mellon Corp has increased its holdings by 23.4%, now owning 50,914 shares valued at $570,000 after acquiring an additional 9,639 shares last quarter. Rhumbline Advisers has also increased its position by 6.7%, bringing their ownership to 25,729 shares valued at $288,000. Lastly, Quest Partners LLC purchased a new stake worth about $91,000. Institutional investors now collectively own 76.95% of Pulse Biosciences' stock.

Analyst Ratings

In terms of analyst ratings, StockNews.com recently downgraded shares of Pulse Biosciences to a "sell" rating, according to their report issued on December 12th.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as an innovative bioelectric medicine company. One of their key products is the CellFX System, which is a software-enabled platform designed to deliver nano-second duration pulses of electrical energy to targeted cells, effectively treating various medical conditions while protecting surrounding non-cellular tissue.

Investment Consideration

Considering investment opportunities in Pulse Biosciences, prospective investors should be aware of recent market trends and performance metrics. While Pulse Biosciences holds a "Hold" rating among analysts, various high-performing stocks have been identified as potentially more favorable investments.

Investment, Shares, Acquisition